Beyond Viral Suppression: The Future of HIV Treatment and the Quest for a Cure

For decades, oral antiretroviral therapy (ART) has transformed HIV from a near-certain death sentence into a manageable chronic condition. Yet, the recent emergence of long-acting injectables and ongoing research into immune-based therapies represent a pivotal advancement, moving the field beyond simply suppressing the virus to potentially achieving a cure. While ART remains the cornerstone of HIV management, scientists are increasingly focused on strategies to eliminate the virus entirely and restore immune function.

The Promise and Limitations of Long-Acting Injectables

Long-acting injectable ART offers significant advantages over daily oral regimens, reducing the frequency of clinic visits and eliminating the need for strict at-home adherence. The National Institutes of Health notes that these injectables, typically administered monthly or every two months, are particularly beneficial for individuals facing challenges with daily pill-taking. Currently, the first complete HIV treatment provided by long-acting injections is a combination of cabotegravir and rilpivirine, marketed as Cabenuva in North America and Australia and Vocabria and Rekambys in Europe. Aidsmap details this treatment option.

However, it’s crucial to understand that these injectables, like oral ART, do not eliminate the virus completely. They suppress viral replication but do not eradicate latent reservoirs of HIV-infected cells. Lifelong adherence to care and maintaining therapeutic drug levels remain essential to prevent viral rebound and the development of drug resistance. The Canadian Medical Association Journal highlights this ongoing need for consistent treatment.

Moving Towards Immune-Mediated Protection

To move beyond indefinite disease management, researchers are exploring therapeutic strategies that harness the power of the immune system to eliminate HIV. A universally effective prophylactic vaccine remains a primary goal, but HIV’s exceptional ability to evade the immune system presents a significant challenge. Despite decades of research, there are no known cases of natural sterilizing immunity to HIV.

Harnessing Broadly Neutralizing Antibodies

One promising approach involves assisting the production of broadly neutralizing antibodies (bnAbs), which can target conserved regions of the HIV protein. However, naturally occurring bnAbs develop slowly, often only after years of chronic infection. Researchers are exploring methods to accelerate this process, including stepwise vaccination using mRNA delivery platforms to activate rare precursor B cells and guide the immune system towards bnAb production. Alternative strategies include direct infusion of long-acting bnAbs and gene-editing approaches to induce bnAb production.

Eliminating Viral Reservoirs

Even with effective viral suppression, HIV establishes latent reservoirs of infected cells that are invisible to the immune system. Therapeutic vaccines, combined with latency-reversing agents (LRAs), offer a potential pathway towards treatment-free remission or a cure. LRAs aim to “shock” latent viruses into transcriptional activity, making them susceptible to immune system targeting. Chromatin remodelers, which alter the structure of chromatin to promote HIV gene expression, are one class of LRAs under development.

Advances in Pediatric HIV Prevention

Newborns at risk of HIV acquisition may be ideal candidates for ART alternatives that offer sustained immune protection or remission. The well-defined at-risk population and the potential to avoid lifelong ART dependence make this a particularly compelling area of research. The unique characteristics of the pediatric immune system may enhance its ability to mount a durable HIV response. Ongoing trials, such as the AbVax trial, are investigating combination therapies including vaccines and bnAb infusion in infants.

Genetically Engineering Infection Resistance

Another innovative approach involves genetically engineering cells to resist HIV infection. Cures have been achieved through stem cell transplants carrying a homozygous CCR5Δ32 genetic mutation, which renders cells resistant to certain strains of HIV. However, this approach is currently limited to individuals with concurrent blood cancers and carries significant risks. More scalable alternatives, such as CRISPR/Cas9 gene editing, are being explored to disrupt HIV co-receptors or excise integrated proviral DNA from host genomes.

The Path Forward

Developing next-generation HIV therapies will likely require a combination of approaches, and a universally effective vaccine may prove challenging to achieve. Initial therapies may be ingenious but inaccessible, requiring adaptation to become cost-effective and deployable in low-resource settings. The success of long-acting injectables sets a high bar for future therapeutic developers, who should prioritize populations underserved by current ART-based interventions. Despite the challenges, the progress made in HIV treatment and prevention over the past four decades is remarkable, and continued research holds the promise of a future where HIV is not just manageable, but curable.